Date: Nov 14, 2015 Source: Technology Network News (
click here to go to the source)
Johnson & Johnson has announced a definitive agreement to acquire Novira Therapeutics, Inc., a privately held, clinical-stage biopharmaceutical company developing novel therapies for curative treatment of chronic hepatitis B virus (HBV) infection.
The acquisition includes Novira’s portfolio of novel antivirals, including its lead candidate, NVR 3-778. Financial terms of the transaction have not been disclosed.
NVR 3-778 is a small molecule, direct acting antiviral, for oral administration in patients with HBV that inhibits the HBV core or capsid protein. HBV core is a novel and promising drug target since it is involved in multiple activities required for viral replication and persistence.
“We are excited about the prospect this acquisition offers to accelerate the development of curative treatments for people affected by chronic hepatitis B,” said William N. Hait, M.D., Ph.D., Global Head, Research & Development, Janssen Pharmaceutical Companies of Johnson & Johnson. “NVR 3-778 offers the potential for efficient suppression of virus production and replication, which could help address the remaining unmet medical needs.”
The closing is subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act and other customary closing conditions. The transaction is expected to close during the fourth quarter of 2015.
“Chronic Hepatitis B is a potentially fatal liver disease with approximately 60 percent of hepatocellular carcinoma attributed to infection with the Hepatitis B virus,” said Lawrence Blatt, PhD Global Head, Infectious Diseases and Vaccines, Janssen and Chief Executive Officer, Alios Biopharma, part of the Janssen Pharmaceutical Companies. “With more than 350 million people affected worldwide we seek to overcome treatment challenges, such as the requirement for people to endure lifelong therapy, through scientific innovation. Combining Novira’s recent breakthroughs with our vast experience in viral diseases we endeavor to deliver novel medicines for patients suffering from this insidious disease".
Johnson & Johnson Expects Lucrative Return on Drug Pipeline
Following the recent announcement of a number of collaborations and upcoming projects, the company hope their pharmaceutical business will continue to grow.
Thursday, May 21, 2015J&J Announces Formation of Ebola Vaccine Development Consortia
Consortia funded through the IMI Ebola+ programme supported by the European Commission.
Friday, January 23, 2015Johnson & Johnson Announces Major Commitment of Up to $200 Million
Commitment to speed Ebola vaccine development and significantly expand production.
Friday, October 31, 2014
Johnson & Johnson to Speed Ebola Vaccine Development, Significantly Expand Production
Company has committed up to $200M to vaccine program in development at its Janssen Pharmaceutical Companies.
Wednesday, October 22, 2014Johnson & Johnson Announces Agreement to Acquire Alios BioPharma
Acquisition strengthens existing pipeline in viral diseases.
Wednesday, October 08, 2014Johnson & Johnson, Dana-Farber Announce Immuno-Oncology Lung Cancer Collaboration
Johnson & Johnson Innovation, Boston and Janssen Biotech, Inc. announced a three-year immuno-oncology lung cancer collaboration with the Dana-Farber Cancer Institute.
Thursday, June 26, 2014Johnson & Johnson to Acquire Aragon Pharmaceuticals, Inc.
Late-stage prostate cancer treatment strengthens oncology pipeline.
Thursday, June 20, 2013Global Cross-Pharmaceutical Clinical Trial Investigator Databank Established
Lilly and Merck are first to join Janssen in this pre-competitive initiative to increase efficiencies in clinical trials.
Friday, November 16, 2012J&JPRD Joins the Simcyp Consortium and Licenses the Simcyp Simulator
J&JPRD is now providing access to the Simcyp Population-based ADME Simulator and Paediatric module to its global network of research & development teams.
Wednesday, May 28, 2008Johnson & Johnson Pharmaceutical Research & Development to Expand new Facility
The expanded facilities in Spring House, Pa., will house drug-development research into biomarkers, structural biology and pharmacogenomics.
Monday, April 23, 2007
The Do’s and Don’ts of SPR Experiments
Surface Plasmon Resonance (SPR) is a technique that is becoming more widely used, particularly by anyone who wants to obtain accurate on (association) and off (dissociation) rates for biomolecular binding. New Method Identifies Up to Twice as Many Proteins and Peptides
An international team of researchers developed a method that identifies up to twice as many proteins and peptides in mass spectrometry data than conventional approaches.Metabolic Profiles Distinguish Early Stage Ovarian Cancer with Unprecedented Accuracy
Studying blood serum compounds of different molecular weights has led scientists to a set of biomarkers that may enable development of a highly accurate screening test for early-stage ovarian cancer.Discovery Provides New Opportunities for Chips
Scientists at the University of Twente's MESA+ research institute have developed a new manufacturing method to create three-dimensional nanostructures.Penn Engineering Team Showcases ‘Eye-on-a-Chip’ Technology
These small plastic chips contain microfluidic channels, carefully designed so that human cells can grow in them in a way that simulates the three-dimensional environments they would normally inhabit in the body.A New Way to Look at MOFs
International study challenges prevailing view on how metal organic frameworks store gases.Major Advance in Crystal Structure Prediction Methods
The Cambridge Crystallographic Data Centre (CCDC) announces that the results of its 6th blind test of crystal structure prediction methods demonstrate significant advancement in in comparison with previous tests.Improving Outcomes for Lung Cancer and Diabetic Patients
Novel technologies have been developed with support from SBRI Healthcare funding.Cancer-Fighting Tomato Component Traced
The metabolic pathway associated with lycopene, the bioactive red pigment found in tomatoes, has been traced by researchers at the University of Illinois. New Way to Force Stem Cells to Become Bone Cells
Potential therapies based on this discovery could help people heal bone injuries or set hardware, such as replacement knees and hips.
Go to LabTube
Go to eposters
About Us | Advertise On This Site | Cookies | Contact Us | Home | Support | Terms & Conditions
©2015 Technology Networks, all rights reserved.
Access to the latest scientific news
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,900+ scientific videos
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!